Nélio Gonçalves
+351 239 820 190
Group at CNC

2017 --- Conducting post-doctoral reasearch at the Center for Neuroscience and Cell Biology (Coimbra, Portugal) on Targeted Therapies for Cancer Stem Cells, funded by CANCEL STEM Consortium (FCT, PIDDAC, FEDER)
2014 – 2016 Conducting post-doctoral research at CNC on Stress and Chronic Diseases: From Mechanisms to Therapeutics for Stress-induced Dysregulation of Circuits, funded by FCT (PT), NAF (USA), DARPA (USA), and FEDER - QREN (EU);
2007 - 2013 - PhD in Pharmaceutical Biotechnology by the Faculty of Pharmacy, University of Coimbra, Portugal
2001 - 2007 - Licenciate in Pharmaceutical Sciences by FFUC, Portugal.

- 11 publications in high impact international peer-reviewed journals (all in Q1): Nature Comm (2016), Ann Neurol (2016 & 2013), Neuropsychopharmacol (2016), Front Cell Neurosci (2016), Hum Mol Genet (2015 & 2014), Mol Psychiatry (2014), J Neuroinflammation (2013), Radiother Oncol (2013) and Brain (2012);
- 4 publications in Conference Proceedings;
- 26 oral communications and 41 poster presentations in national and international scientific meetings.

- Doctoral Programmes: in Experimental Biology and Biomedicine (PDBEB-CNC, UC), and in Health Sciences (Faculty of Medicine, UC);
- Master’s degree in Pharmaceutical Biotechnology (FFUC);
- Supervisor of 1 completed Master Thesis in Biochemistry (FCTUC), 1 ongoing Master Thesis in Biomedical Research (FMUC); and 1 BSc traineeship in Molecular and Cell Biology (FCTUC)



Area of Research: 

Combining solid Biomedicine expertise with Nanotechnology will potentiate the identification of multiple and effective novel targets on brain dysfunction (Neuroscience field) and on abnormal out-of-control cells growth (Oncology field) also clarifying their underlying intra- and extra-cellular signaling pathways, which are essential to foster novel and successful therapeutic tools and to pave the way for their translations for clinical application.

Research Summary: 
Selected Publications: 

1. Gonçalves N, Simões AT, Prediger RS, et al. Caffeine alleviates motor deficits in a mouse model of spinocerebellar ataxia. Annals of Neurology (2016) DOI: 10.1002/ana.24867. IF 2016: 9.64

2. Silva SV, Haberl MG, Zhang P, Bethge P, Lemos C, Gonçalves N, et al. Early synaptic deficits in the APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A2A receptors. Nature Communications (2016), 7:11915 DOI: 10.1038/ncomms11915. IF 2016: 11.47

3. Li P, Rial D, Canas P, Yoo JH, Li W, Zhou X, Wang Y, van Westen GJP, Payen MP, Augusto E, Gonçalves, N, et al. Optogenetic activation of intracellular adenosine A2A receptor signaling in hippocampus is sufficient to trigger CREB phosphorylation and impair memory. Molecular Psychiatry (2015) DOI: 10.1038/mp.2014.182. IF 2015: 15.15

4. Simões AT, Gonçalves N, Nobre RJ, et al. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. Human Molecular Genetics (2014), 23:4932-44. DOI: 10.1093/hmg/ddu209. IF 2014: 7.69

5. Gonçalves N. Simões AT, Cunha RA, Pereira de Almeida L. Caffeine and adenosine A2A receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Annals of Neurology (2013), 73:655-666. DOI: 10.1002/ana.23866. IF 2013: 11.19 (Best Paper Award 2014, by SPN)

6. Simões AT, Gonçalves N, Koeppen A, et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain (2012), 135:2428-2439. DOI:10.1093/brain/aws177. IF 2012: 10.87 (Best Paper Award 2013, SPN)

© 2017 CNC - Center for Neuroscience and Cell Biology powered by ponto.C